Polarityte Inc Quick Ratio (PTE) starting from the first quarter 2023 to first quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Polarityte Inc   (NASDAQ: PTE)

Polarityte Inc 's Quick Ratio

PTE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2023, Quick Ratio fell to 2.94 below Polarityte Inc average.

Within Biotechnology & Pharmaceuticals industry 138 other companies have achieved higher Quick Ratio than Polarityte Inc in first quarter 2023. While Quick Ratio total ranking in the first quarter 2023 has deteriorated compared to the prior quarter from 536 to 1160.

Explain Quick Ratio?
How much Cash & cash equivalents PTE´s has?
What are PTE´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PTE Quick Ratio (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1
Y / Y Current Liabilities Change -69.17 % -55.4 % -51.22 % -45.41 % -28.42 %
Y / Y Cash & cash equivalent Change -65.85 % -40.92 % -41.16 % -37.09 % -49.72 %
Quick Ratio MRQ 2.94 5.54 5.75 5.84 2.66
PTE's Total Ranking # 1160 # 536 # 717 # 720 # 1286
Seq. Current Liabilities Change 5.08 % -26.15 % -20.3 % -50.15 % 52 %
Seq. Cash & cash equivalent Change -44.14 % -28.88 % -21.56 % 9.59 % -3.37 %



Quick Ratio first quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 139
Healthcare Sector # 561
Overall Market # 1160


Quick Ratio Statistics
High Average Low
18.2 4 0.5
(Jul 31 2018)   (Oct 31 2011)




Financial Statements
Polarityte Inc 's Current Liabilities $ 2 Millions Visit PTE's Balance sheet
Polarityte Inc 's Cash & cash equivalent $ 6 Millions Visit PTE's Balance sheet
Source of PTE's Sales Visit PTE's Sales by Geography


Cumulative Polarityte Inc 's Quick Ratio

PTE's Quick Ratio for the trailling 12 Months

PTE Quick Ratio

 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth -55.77 % -42.12 % -40.67 % -37.72 % -34.3 %
Y / Y Cash & cash equivalent TTM Growth -44.47 % -42.72 % -39.12 % -27.49 % -15.79 %
Quick Ratio TTM 5.16 4.33 4.15 4.11 4.11
Total Ranking TTM # 4469 # 4476 # 4475 # 858 # 4497
Seq. Current Liabilities TTM Growth -31.6 % -14.27 % -14.04 % -12.25 % -10.5 %
Seq. Cash & cash equivalent TTM Growth -18.46 % -10.61 % -13.09 % -12.33 % -15.88 %

Quick ratio ranking by company, industry and sector >> Back to PTE Financial Strength Comparisons >> Go to Compare PTE Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Polarityte Inc 's average Cash & cash equivalent, this led to increase in in Polarityte Inc 's Quick Ratio to 5.16, above PTE average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 191 other companies have achieved higher Quick Ratio than Polarityte Inc . While Quick Ratio overall ranking has improved so far to 4469, from total ranking during the twelve months ending fourth quarter 2022 at 4476.

Explain Quick Ratio?
How much Cash & cash equivalents PTE´s has?
What are PTE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 192
Healthcare Sector # 1157
Within the Market # 4469


trailing twelve months Quick Ratio Statistics
High Average Low
9.68 4.83 3.08
(Mar 31 2019)   (Dec 31 2020)




Companies with similar Quick Ratio in the quarter ending Mar 31 2023, within Biotechnology & Pharmaceuticals Industry Quick RatioMar 31 2023 MRQ Cash & cash equivalentMar 31 2023 MRQ Current Liabilities
Black Diamond Therapeutics Inc   8.05 $ 103.366  Millions$ 12.847  Millions
Surrozen Inc   7.93 $ 61.746  Millions$ 7.789  Millions
Allogene Therapeutics Inc   7.91 $ 471.224  Millions$ 59.585  Millions
Bioatla Inc   7.80 $ 192.687  Millions$ 24.711  Millions
Miromatrix Medical inc   7.70 $ 25.605  Millions$ 3.325  Millions
Inhibrx Biosciences Inc   7.66 $ 234.254  Millions$ 30.582  Millions
Tenaya Therapeutics Inc   7.66 $ 147.813  Millions$ 19.305  Millions
Omega Therapeutics Inc   7.56 $ 136.787  Millions$ 18.104  Millions
Acumen Pharmaceuticals Inc   7.11 $ 62.410  Millions$ 8.779  Millions
Lenz Therapeutics Inc   7.01 $ 100.465  Millions$ 14.341  Millions
Surface Oncology Inc   6.92 $ 102.055  Millions$ 14.750  Millions
Exscientia Plc  6.78 $ 592.421  Millions$ 87.319  Millions
Alector Inc   6.74 $ 669.329  Millions$ 99.300  Millions
Ginkgo Bioworks Holdings Inc   6.29 $ 1,206.086  Millions$ 191.704  Millions
Dyadic International Inc   6.26 $ 11.737  Millions$ 1.875  Millions
Tectonic Therapeutic Inc   6.20 $ 72.326  Millions$ 11.672  Millions
Kodiak Sciences Inc   6.11 $ 421.191  Millions$ 68.938  Millions
Senti Biosciences Holdings Inc   5.92 $ 76.106  Millions$ 12.866  Millions
Gritstone Bio Inc   5.91 $ 145.808  Millions$ 24.672  Millions
Biontech Se  5.72 $ 13,263.936  Millions$ 2,318.960  Millions
Humacyte Inc   5.58 $ 131.677  Millions$ 23.601  Millions
Editas Medicine Inc   5.57 $ 318.439  Millions$ 57.155  Millions
Elevation Oncology inc   5.46 $ 73.929  Millions$ 13.534  Millions
Twist Bioscience Corporation  5.38 $ 387.658  Millions$ 72.108  Millions
Cognition Therapeutics inc   5.20 $ 38.810  Millions$ 7.465  Millions
Fresh Tracks Therapeutics Inc   5.19 $ 10.764  Millions$ 2.073  Millions
Recursion Pharmaceuticals Inc   5.13 $ 473.145  Millions$ 92.150  Millions
X4 Pharmaceuticals Inc  5.10 $ 93.406  Millions$ 18.308  Millions
Poseida Therapeutics Inc   5.08 $ 247.201  Millions$ 48.690  Millions
Opthea Limited  5.07 $ 95.115  Millions$ 18.743  Millions

Date modified: 2026-09-08T15:10:58+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.